Table 1.
Reporting of medication adherence in pivotal clinical trials
| Studies (N) |
Adherence in article N (%) |
Adherence in supplementary material N (%) |
No | |
| Total | 56 | 11 (20%) | 26 (46%) | 19 (34%) |
| Cancer type | ||||
| Basal cell | 1 | 1 (100%) | 0 | 0 |
| Breast | 8 | 1 (12.5%) | 5 (62.5%) | 2 (25%) |
| Colorectal | 1 | 0 | 1 (100%) | 0 |
| Hepatocellular | 2 | 0 | 1 (50%) | 1 (50%) |
| Lung | 21 | 3 (14%) | 9 (43%) | 9 (43%) |
| Melanoma | 10 | 2 (20%) | 4 (40%) | 6 (60%) |
| Ovarian | 5 | 3 (60%) | 1 (20%) | 1 (20%) |
| Prostate | 2 | 0 | 2 (100%) | 0 |
| Renal | 4 | 1 (25%) | 2 (50%) | 1 (25%) |
| Thyroid | 2 | 0 | 1 (50%) | 1 (50%) |
| Study design | ||||
| Double-blind | 22 | 7 (32%) | 10 (45%) | 5 (23%) |
| Open label | 31 | 4 (13%) | 16 (52%) | 11 (35%) |
| Control arm | ||||
| Comparator | 18 | 2 (11%) | 12 (67%) | 4 (22%) |
| Placebo | 11 | 4 (31%) | 5 (45%) | 2 (19%) |
| Placebo+drug | 10 | 2 (20%) | 5 (50%) | 3 (30%) |
| Phase | ||||
| I | 4 | 0 | 0 | 4 (100%) |
| I/II | 1 | 0 | 0 | 1 (100%) |
| II | 15 | 4 (27%) | 5 (33%) | 6 (40%) |
| III | 36 | 7 (20%) | 21 (58%) | 8 (22%) |